[1] O'Mahony C,Elliott PM. Prevention of sudden cardiac death in
hypertrophic cardiomyopathy [J]. Heart,2014, 100 (3) :
254-260.
[2] Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young
competitive athletes: analysis of 1866 deaths in the United
States, 1980–2006 [J].Circulation, 2009, 119:1085–1092.
[3] Cecchi F,Maron BJ,Epstein SE.Long-term outcome of patients
with hypertrophic cardiomyopathy successfully resusci?
tated after cardiac arrest [J]. J Am Coll Cardiol, 1989, 13:
1283-1288.
[4] McKenna WJ,Behr ER. Hypertrophic cardiomyopathy: Man?
agement, risk stratification, and prevention of sudden death
[J].Heart, 2002, 87:169-176.
[5] Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hy?
pertrophic cardiomyopathy:Identification of high risk patients
[J].J Am Coll Cardiol, 2000, 36:2212-2218.
[6] 李新立.肥厚型心肌病患者心源性猝死相关预测指标的临床价
值[J].内科理论与实践,2012,7 (5):334-337.
[7] Haghjoo M, Faghfurian B, Taherpour M, et al. Predictors of
syncope in patients with hypertrophic cardiomyopathy [J].
Pacing Clin Electrophysiol,2009,32(5):642-647.
[8] Spirito P, Maron BJ. Risk stratification for sudden death in hy?
pertrophic cardiomyopathy [J]. Zhonghua Xin Xue Guan
Bing Za Zhi, 2009, 37(4):294-297. Chinese.
[9] Spirito P,Bellone P,Harris KM,et al. Magnitude of left ven?
tricular hypertrophy and risk of sudden death in hypertrophic
cardiomyopathy [J].N Engl J Med, 2000, 342:1778-1785.
[10] Elliott PM,GimenoBJ,MahonNG,et al.Relation between se?
verity of left ventricular hypertrophy and prognosis in patients
with hypertrophic cardiomyopathy [J]. Lancet,2001,357:
420-424.
[11] Olivotto I,Gistri R,Petrone P, et al. Maximum left ventricularthickness and risk of sudden death in patients with hypertrophic
cardiomyopathy [J]. J Am Coll Cardiol,2003,41(2):315-
321.
[12] Monserrat L,Elliott PM, Gimeno JR, et al. Non- sustained
ventricular tachycardia in hypertrophic cardiomyopathy: an in?
dependent marker of sudden death risk in young patients [J].
J Am Coll Cardiol, 2003, 42(5):873-879.
[13] Sadoul N,Prasad K,Elliott PM,et al. Prospective prognostic
assessment of blood pressure response during exercise in pa?
tients with hypertrophic cardiomyopathy [J]. Circulation,
1997, 96:2987-2991.
[14] Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable
cardioverter- defibrillators for the prevention of sudden death in
patients with hypertrophic cardiomyopathy [J]. N Engl J
Med, 2000, 342(6):365-373.
[15] Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventric?
ular outflow tract obstruction on clinical outcome in hypertro?
phic cardiomyopathy [J]. N Engl J Med, 2003, 348:295-
303.
[16] Kofflard MJ, Ten Cate FJ, Van der Lee C,et al. Hypertrophic
cardiomyopathy in a large community- based population: clini?
cal outcome and identification of risk factors for sudden cardiac
death and clinical deterioration [J].J Am Coll Cardiol, 2003,
41(6):987-993.
[17] Efthimiadis GK, Parcharidou DG, Giannakoulas G, et al. Left
ventricular outflow tract obstruction as a risk factor for sudden
cardiac death in hypertrophic cardiomyopathy [J].Am J Car?
diol, 2009, 104(5):695-699.
[18] Ackerman MJ, VanDriest SL, Ommen SR,et al. Prevalence
and age- dependence of malignant mutations in the beta- myo?
sin heavy chain and troponin T genes in hypertrophic cardiomy?
opathy: a comprehensive outpatient perspective [J]. J Am
Coll Cardiol, 2002, 39(12):2042-2048.
[19] 闫倩,刘兴鹏.肥厚型心肌病的危险分层:新的猝死预测指标
[J].心脏病学进展,2012,33 (3):289-291.
[20] Bruder O,Wagner A,Jensen CJ,et al.Myocardial scar vi?
sualized by cardiovascular magnetic resonance imaging predicts
major adverse events in patients with hypertrophic cardiomyop?
athy [J].J Am Coll Cardiol,2010,56: 875-887.
[21] Gersh BJ,Maron BJ,Bonow RO,et al.2011 ACCF/AHA
guideline for the diagnosis and treatment of hypertrophic cardio?
myopathy: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Prac?
tice Guidelines [J].Circulation,2011,124: e783-e831.
[22] Frenneaux Michael P. Assessing the risk of sudden cardiac
death in a patient with hypertrophic cardiomyopathy [J].
Heart, 2004, 90:570-575.
[23] Melacini P, Maron B J, Bobbo F, et al. Evidence that pharma?
cological strategies lack efficacy for the prevention of sudden
death in hypertrophic cardiomyopathy [J]. Heart, 2007, 93:
708–710.
[24] Ly HQ, Greiss I, Talakic M, et al. Sudden death and hypertro?
phic cardiomyopathy: a review [J].Can J Cardiol,2005,21(5):
441-448. Review.
[25] Lin G, Nishimura RA, Gersh BJ, et al. Device complications
and inappropriate implantable cardioverter defibrillator shocks
in patients with hypertrophic cardiomyopathy [J]. Heart,
2009, 95(9):709-714.
[26] 刘烈,陈东骊,陈泗林,等.埋藏式心脏复律除颤器在心脏性猝死
一级预防中的作用[J]. 南方医科大学学报, 2013, 33(8):
1229-1231.
[27] Maron BJ, Spirito P, Ackerman MJ, et al. Prevention of Sud?
den Cardiac Death With Implantable Cardioverter- Defibrilla?
tors in Children and Adolescents With Hypertrophic Cardiomy?
opathy [J].J Am Coll Cardiol, 2013,61(14):1527-1535.
[28] Maron BJ,Spirito P,Shen W,et al. Implantable Cardioverter
Defibrillators and Prevention of Sudden Cardiac Death in Hyper?
trophic Cardiomyopathy[J].JAMA, 2007, 298(4):405-412.
[29] Andrzej P, Longina M, Mariusz P, et al. Implantable cardio?
verter-defibrillators in patients with hypertrophic cardiomyopa?
thy- dilemmas and difficulties [J]. Kardiol Pol, 2005, 63:
391-397.
[30] Woo A,Monakier D,Harris L, et al. Determinants of implant?
able defibrillator discharges in high-risk patients with hypertro?
phic cardiomyopathy [J].Heart, 2007, 93(9):1044-1045.
[31] 崔宏丽,赵鹏,王怡璐.肥厚型心肌病与心源性猝死[J].中国分
子心脏病学杂志,2013,6:767-771.